Table 6.
Comparison of the areas under ROC for NLR and other biomarkers to predict future exacerbations and low % FEV1 (% FEV1 < 50%)
| Exacerbation | AUC (95% CI) |
| NLR | 63.4 (55.0–71.7) |
| Neutrophil count | 55.2 (46.3–64.2) |
| Lymphocyte count | 59.2 (50.8–67.6) |
| Eosinophil count | 51.2 (41.9–60.6) |
| CRP | 54.3 (45.2–63.4) |
| SAA | 59.4 (50.5–68.3) |
| % FEV1 < 50% | AUC (95% CI) |
| NLR | 64.2 (56.9–71.6) |
| Neutrophil count | 55.3 (47.3–63.2) |
| lymphocyte count | 59.8 (52.3–67.3) |
| Eosinophil count | 51.5 (43.4–59.6) |
| CRP | 55.5 (47.7–63.5) |
| SAA | 57.7 (49.8–65.6) |
NLR Neutrophil-to-Lymphocyte ratio, CRP C-reactive protein, SAA serum amyloid A